Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Teehan Brendan

2. Date of Event Requiring Statement (MM/DD/YYYY) 11/1/2021

3. Issuer Name and Ticker or Trading Symbol

ACADIA PHARMACEUTICALS INC [ACAD]

(Last) (First) (Middle)

C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
EVP, COO, Head of Commercial /

(Street)

SAN DIEGO, CA 92130

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	807	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	⁽¹⁾	7/15/2028	Common Stock	52500	$16.87	D
Employee Stock Option (Right to Buy)	⁽²⁾	4/28/2029	Common Stock	10993	$25.12	D
Employee Stock Option (Right to Buy)	⁽³⁾	1/5/2030	Common Stock	9336	$42.81	D
Employee Stock Option (Right to Buy)	⁽⁴⁾	2/22/2031	Common Stock	8152	$49.74	D
Restricted Stock Units	⁽⁵⁾	⁽⁵⁾	Common Stock	3134	⁽⁶⁾	D
Restricted Stock Units	⁽⁷⁾	⁽⁷⁾	Common Stock	3859	⁽⁶⁾	D
Restricted Stock Units	⁽⁸⁾	⁽⁸⁾	Common Stock	4427	⁽⁶⁾	D

Explanation of Responses:
(1)	25% of the 70,000 shares originally subject to the stock option vested and became exercisable on July 16, 2019, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
(2)	25% of the shares subject to the Stock Option vested and became exercisable on April 29, 2020, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
(3)	25% of the shares subject to the Stock Option vested and became exercisable on January 6, 2021, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
(4)	25% of the shares subject to the Stock Option vest and become exercisable on February 23, 2022, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
(5)	50% of the shares subject to the restricted stock units vest on each of April 29, 2022 and April 29, 2023.
(6)	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
(7)	One-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024.
(8)	The restricted stock units vest in four equal annual installments beginning February 23, 2022.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Teehan Brendan C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO, CA 92130			EVP, COO, Head of Commercial